Nº 3 | Volume 12 | 2013 | 10.00 € | ISSN 1618-8276 | A 60711 |
European Biotechnology News Science & Industry
CENTRAL EUROPE
Roche given green light for breast-cancer antibody drug NORTHERN EUROPE
T P R E E EXC
FRE
Scandinavian research alliance screens for novel antibiotics Special
Intellectual Property in the life sciences industry WESTERN EUROPE
Irish Public-Private Partnership ploughs D300m into research SOUTHERN EUROPE
Antibiotics
from the ocean floor
Chiesi Farmaceutici set to take over Cornerstone Therapeutics Eastern EUROPE
Gedeon Richter forms joint venture with China’s Rxmidas science & technology
Swiss researchers map allosteric interactions of bacterial proteins
Sure we’re proudSure of Rembrandt. we’re But we prefer proud of Rembrandt. modern art. But we prefer modern art.
The modern art of Investment Banking. modern art of FromThe Amsterdam, Holland. Investment Banking. From Amsterdam, Holland.
N –º 3 | Volume 12 | 2013
Euro|Biotech|News
Intro
FREE EXCERPT
Editorial
Personalised healthcare has to reach the patient Dr. Hagen Pfundner, Chairman of the German Association of Research-Based Pharmaceutical Companies (vfa) and General Manager of German Roche Pharma AG
T
Hagen Pfundner joined Roche Pharma AG in Germany in 1992. Since 2006, he has held the post of General Manager at Roche Pharma AG in Germany. Since 2008, he has also been a member of the executive board of the German pharma association vfa.
h e use of diagnostic testing is at the centre of Personalised Healthcare (PHC), not only for classifying a disease but also for determining which therapy will be most suitable for an individual patient or a stratified group of patients suffering from that disease. It is all about improving outcomes and tolerability. This concept keeps transforming oncology, and has made its debut in other therapeutic areas like neurology as well. PHC represents not only medical progress, but also highlights the potential to improve cost-efficiency of healthcare delivery by helping to avoid ineffective or even harmful therapies. To fulfill this potential, however, it must find its way into routine healthcare practice. Until now, this has all too often remained a long and winding road. The European Medicines Agency (EMA) and the European Commission embraced the concept of PHC from the beginning, and continue to encourage manufacturers to include up-front testing (patient stratification) in clinical trials design and subsequently in labelling for new drugs, provided the scientific evidence is sound. However, drug approval by the European and national health authorities is only one step on the “road to the patient”. Delays most often occur when it comes to including newly-defined tandems of a drug and a diagnostic test (companion diagnostic) in national reimbursement schemes. Procedures and processes for this step are different in every European country, but there appears to be a common theme: no healthcare system is prepared to handle the situation in a synchronised fashion or within a reasonable time frame. In the out-patient setting, a newly-approved drug is reimbursed following health authority approval, but a new companion diagnostic test – even if mandatory by label – is not. These reimbursement decisions are made by a different body made
up of health insurance companies and associations of office-based physicians that organise physician fees. In the past, decisions have often taken several years. In the US, the Food & Drug Administration (FDA) is moving towards encouraging regular testing as the preferred model for companion diagnostics in PHC. It has issued guidance focusing on the dependency of Rx and Dx coapproval, while the tests have been provided as a service by specific laboratories. So while PHC is meant to shorten the time it takes for a patient to receive the most suitable treatment, in practice medical treatment is often delayed for many patients due to a misalignment of the two divergent reimbursement systems for drugs and companion diagnostics. This is unacceptable for modern European healthcare systems, and provides a disincentive for pharmaceutical and diagnostic companies. The irony is that while the scientific advances of PHC have opened the door to significant improvements in therapeutic and cost efficiency, the current healthcare systems are not equipped to benefit from them. Last but not least, the barriers also run counter to government efforts and support aimed at making Europe the leader in PHC research. There is no “one size fits all” approach in Europe when it comes to including innovative PHC treatments in national reimbursement schemes. But national stakeholders should increase their efforts to resolve this in their countries – and not just in their own interest. Patients, physicians and innovators deserve it! B
3
4
N –º 3 | Volume 12 | 2013
Euro|Biotech|News
CIRCUL ATION
FREE EXCERPT
European Biotechnology News is published in co-operation with the following organisations: European Biotechnology
CMYK
Net work
Europe: european-biotechnology.net
Blue: 100/15/0/35 Orange: 0/75/90/0
Germany: biodeutschland.org
Switzerland: swissbiotech.org
Council of European BioRegions
Europe: cebr.net
Europe: ebe-biopharma.org
Europe: eapb.org
Europe: europabio.org
Norway: biotekforum.no
Ireland: ibec.ie/ibia
Finland: finbio.net
Denmark: danskbiotek.dk
Sweden: swedenbio.com
The Netherlands: niaba.nl
Belgium: bio.be
Spain: asebio.com
France: france-biotech.org
Italy: assobiotec.it
Hungary: hungarianbiotech.org
EuroBiotechNews covers the biotechnology sector of the current 27 EU member states, Norway and Switzerland. If you would like to subscribe, please refer to Portugal: www.apbio.pt
www.eurobiotechnews.eu
N –º 3 | Volume 12 | 2013
contents
FREE EXCERPT
Insight EU programme Horizon 2020 faces budget cuts; Heard in Brussels
5
Euro|Biotech|News
Cover Story 10
Industry leaders lobby for second generation biofuels; EU improves pharma safety; The billion-euro brain simulation 12 ISAAA: Global GMO acreage reaches new high 14 IMI launches European Lead Factory 14 Experts to monitor EU bioeconomy; Cancer biobanking; IP Flash
16
Regulatory Affairs Update on clinical trials
18
Breaking news from the EMA
20
Economic Focus on newsflow and dividends
21
Stock markets
22
47
Regional News Northern Europe
24
Central Europe
26
Western Europe
28
Southern Europe
30
Eastern Europe
32
6
Decades of antibiotic use and overuse of have driven the evolution of a new generation of resistant superbugs. Because investing in antimicrobials usually brings a poor return, however, drug developers have not come up with replacement antibiotics for decades. Now experts are sounding the alarm. If nothing is done, infections that were once easy to treat could again become major killers in the next twenty years. Researchers now hope that help could come from the depths of the sea.
Services
Special
Perspectives A plancental malaria vaccine
Into the deep – antibiotics from the seabed
Partners & Associations
Intellectual Property IP in Life Sciences: Focus on personalised healthcare
35
Interview Dimitrios Tzalis: IP protection within the European Lead Factory
36
Patents on genes
38
Outlicensing in the life sciences industry
42
4
Biopeople News from Nanobiotix; Prosensa Therapeutics; The Louis-Jeantet Foundation; Prosonix; Novartis AG and Probiogen
45
Company index
46
Events What’s on in March–April 2013
49
Encore
50
Imprint European Biotechnology News is published monthly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, E-Mail: service@eurobiotechnews. eu; Internet: www.eurobiotechnews.eu, Publisher: Andreas Mietzsch, Editorial Team: Thomas Gabrielczyk (Managing Editor), Derrick Williams (Co-editor), Dr. Patrick Dieckhoff, Dr. Bernd Kaltwaßer, Dr. Martin Laqua; Advertising: Oliver Schnell, +49-30-2649-2145, Advertising USA: Avani Media, Inc. , Leslie Hallanan, Tel.: +1-415-331-2150 , Fax: +1-415-289-0402, E-Mail: leslie@avanimedia.com; Distribution: Angelika Werner, +49-30-2649-2140; Printed at: Druckhaus Humburg, Bremen; Graphic Design: Michaela Reblin. European Biotechnology Science & Industry News is only regularly available through subscription at BIOCOM AG. Annual subscription fees: € 100.00, Students € 50.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within 2 weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least 6 weeks before the date of expiry. Failures of delivery which BIOCOM AG is not responsible for do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: © rapture, fotolia.com ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.
10
N –º 3 | Volume 12 | 2013
Euro|Biotech|News
INSIGHT EUROPE Horizon 2020
Budget battle
Heard in Brussels M
A Brussels – It was less than science lobbyists had hoped for. The heads of EU Member States in February decided not to follow the Commission‘s a80bn budget proposal for the innovation programme Horizon 2020 (2014-2020) in their negotiations over the long-term EU budget. However, the exact figures within the de facto a908bn EU household remain ambiguous. While a spokesman for EU Research Commissioner Maire Geoghegan-Quinn said “calculations made over the weekend” after the EU Council indicated “a budget of a70.96bn”, an internal paper from Commission Secretary General Catherine Day fixes the sum at about a68bn. This is a rise of a17bn-a20bn compared to the a50.5bn in the current FP7 R&D programme.
Joining the true budget battle Right up to the decision, the European Research Council (ERC) and the European Round Table of Industrialists (ERT) had lobbied to greenlight a80bn over the seven years, and now have been given a leg up from the European Parliament‘s four largest groups. “The … Parliament cannot accept (today’s) deal in the European Council as it is. … the real negotiations will start now with the European Parliament,” said Joseph Daul on behalf of the EPP, Hannes Swoboda on behalf of the S&D, Guy Verhofstadton on behalf of ALDE, and Rebecca Harms and Daniel Cohn-Bendit on behalf of the Greens/EFA. Just like the ERT and the ERC, the MEPs fear “any reduction in funding to support excellent research will result in Europe having limited means to attract outstanding talent in a highly competitive global market.” Expectations inside the Commission are that all the Horizon 2020 programmes will share equally in the cut from the original proposal. Under FP7, health research got almost a5.6bn, while bioeconomy R&D received around a1.7bn. The budget battle is now being viewed as a major test of the European Parliament’s independence from national governments. B
FREE EXCERPT
A promising transition to Horizon 2020 for SMEs
Brussels – The end of the FP7 process has been a busy one, with a rush to grab the last EC funds before we all get thirsty in the break between FP7 and the launch of Horizon 2020 in 2014. And my, hasn’t it been a busy time for all you clever SMEs out there! The results are in for the part of the Health call targeting SMEs (Innovation 2), with proposals requiring 50% of funding going to SMEs. There were two main topics in the call: the first on anti-infective research and the second in translating work from previous framework projects. The EC has put its money where its mouth is for SMEs, which is great to see, with a140m available for the call. As well as targeting funding to SMEs, it has also made great strides in bringing a business focus to evaluation, with 72% of the evaluators coming from companies. And the results? Pretty good. 58% of all that lovely money went to SMEs, with Germany, UK, France and the Netherlands taking the four top spots (Italy used to be right up there, I recall from my distant youth, but is looking a little sorry for itself these days). The average pass rate is about 40% for the UK, France and Netherlands, which is pretty good, while Germany has gone for a ‘pile ‘em high and sell ‘em cheap’ approach, with loads of proposals but a pass rate of just 25%. A nice fact is that the targeted time from deadline to contract signature is to be just five months. DG Research & Industry has worked to respond to critics on access for SMEs and slow timescales, and this should be remembered when you next moan about EC funding. We’re still waiting for the results of the main programme in health – which had 35 topics and a679m to spend – but there’s plenty to take home from this first result. Europe knows that it has to monetise its innovative research. The fact that we have stopped buying cars and other stuff made
Claire Skentelbery, Secretary General of the European Biotechnology Network
in factories in Europe has turned slick political phrases about innovation into urgent reality. We need the money back from research, and we need it now. It’s fantastic to see that the largest funding programme in Europe is doing just that; money is being channelled to SMEs, the translators of research from a dream to commercial reality. While the market in Europe won’t fund early stage commercial work (you idiots), governments and the EC are stepping into the gap. It’s also a relief to see funding of translational work from previous Framework projects. Funding a single part of the value chain will rarely push a product to market, but sustained funding on evidence-based progress is sensible and a good use of money, and it also strengthens productive partnerships that keep their eye on the market. FP7 has evolved over its lifetime, and the early signs from Horizon 2020 indicate that the focus on turning technologies into economic returns will continue. Keep up the good work, girls and boys of DG Research & Industry, and we look forward to enjoying the fruits of the Framework tree! B
12
N –º 3 | Volume 12 | 2013
Euro|Biotech|News
INSIGHT EUROPE
News Horsemeat scandal
Brussels – After horsemeat admixtures were identified in more than 13 European contries since mid-January, the European Commission has obliged Member States to intensify DNA testing of beef products. EU Health Commissioner Tonio Borg announced that the programme of random tests would begin in March and report for the first time on 15 April. Testing will continue until at least June. In all, 2,500 samples of processed beef products and 4,000 samples from slaughterhouses are slated for testing. The associated costs should be low; kits that include 100 PCR tests are available for a560.
M
EUropean union
Bouncing back on biofuels A Brussels – Seven industry leaders have launched an initiative to support R&D and market uptake of second-generation biofuels in Europe’s transport sectors. The “Leaders of Sustainable Biofuels” say that “biofuels made from non-food feedstocks represent one of the major industrial opportunities … (to deliver) sustainable energy.” The initiative was launched last month in Brussels. The executives from leading biofuel producers and airlines (Italian PET producer Chemtex, British Airways, Dutch pyrolysis oil producer
Getting the most out of biofuel crops
BTG, Hungarian syngas specialist Chemrec, biorefinery provider Clariant, Danish energy giant Dong Energy and Finnish UPM) are lobbying for a “policy and regulatory framework enabling long-term investment.” The move comes after a U-turn in the European Commission’s policy regarding maize or wheat-based biofuels (see EuroBiotechNews 10/2012). Industry players called the announcement that the bloc was capping biofuel production from food-based feedstocks at 5% by 2020 (10% was planned) “a catastrophe”. In a manifesto, the industry leaders insist second-generation biofuels can reduce greenhouse gas emissions by at least 65%. They want to work out a common strategy to accelerate market penetration and boost R&D in emerging biofuel technologies through public-private partnerships. Specifically, they want to “stimulate EU policy” to develop globally accepted sustainability certification. Their aims include communicating the advantages of nonfood biofuels to the public and lobbying for funding. B
IMI
Funding
Safety brokers
Mapping thought
A London – The PROTECT project on pharma safety has delivered two databases for pharmacovigilance-relevant and pharmacoepidemiological data. Set up by the FP7funded consortium of 33 partners, the first database provides information about drug consumption in 17 of the 27 EU Member States, and will be expanded continously. The second – a so-called ADR database – is a compilation of adverse drug reactions. It is aimed at quickly identifying and filtering incoming information on unwanted side effects from clinical trials, physicians and agencies. PROTECT is part of the Innovative Medicines Initiative (IMI). B
A Brussels/Lausanne – The Human Brain Project (HBP) has been selected by the European Commission as one of two FET Flagship Initiatives. Overall, its 87 contributors – who will try to simulate the human brain in a project lasting a decade – are set to be funded with a1bn. Half of that will come from the Commission. a58m will already flow this year, while future funding will be continued from the Horizon 2020 budget. Henry Markram from EPFL (Switzerland) will lead the effort to reconstruct the brain in supercomputer-based models and simulations. The researchers will start work at the end of 2013. B
Unitary patent court
Brussels – EU ministers have paved the way for the implementation of a unitary patent system in Europe. By mid-February, a majority of 24 Member States had signed an international agreement establishing a Unified Patent Court (UPC). Its first instance will be headquartered in Paris, with subsidiaries in London and Munich. The appeal instance will be located in Luxembourg. Up to now, a wide range of national courts and authorities have made decisions on infringement and validity questions involving Euro pean patents. Biotech industry associations like BIA and EuropaBio welcomed the decision, as a single court promises to provide much simpler and more cost-effective IP protect ion. However, not every country is on board. Poland has opted out, while Spain has also indicated it will not take part. The two EU regulations on the unitary patent entered into force on 20 January 2013, but still have to be ratified to come into force.
© KIT
M
FREE EXCERPT
46
N –º 3 | Volume 12 | 2013
Euro|Biotech|News
Company And Advertiser Inde x A
AbCheck s.r.o. (CR)… …………………………… 32 Aber Instruments (UK)…………………………… 26 Ablynx NV (B)… ………………………… 18, 23, 29 AC Immune SA (CH)……………………………… 26 Actavis Group (IS)……………………………… 20, 45 Addex Pharma (CH)… …………………………… 50 Addex Therapeutics (CH)………………………… 27 Agendia B.V. (NL)… ……………………………… 35 Aglaris Cell S.L. (E)… …………………………… 31 Alain Oncologie Consulting (F)… ……………… 45 Amgen Inc. (USA)……………………………… 18, 45 Arcticzymes AS (N)… …………………………… 25 Ark Therapeutics (UK)… ………………………… 45 Astra Zeneca (GB/S)……………………………… 15 Aventis Pharma (F)… …………………………… 45
B
Baker Botts LLP (USA)… ………………………… 35 BASF (GER)… …………………………………… 14 Baxter International… …………………………… 27 Bayer AG (GER)………………………………… 15, 18 Bayer CropScience GmbH (GER)………………… 27 Bio-Tech Consulting (PL)… ……………………… 32 BIOCOM AG (GER)… …………………………… 44 BioGeneration Ventures (NL)… ………………… 22 BioMarin Europe Ltd. (UK)… …………………… 20 Biotecnol S.A. (PT)… …………………………… 31 Biotie Therapies Corp. (FI)… …………………… 24 Biotie Therapies Corp. (FI)… …………………… 29 BioTOP Berlin-Brandenburg (GER)… …………… 17 BLIRT (PL)… ……………………………………… 32 BlueSens gas sensor GmbH (GER)…………… 47, 48 Boehmert & Boehmert (GER)… ………………… 38 Bone Therapeutics (B)…………………………28, 29 Bristol-Myers Squibb (USA)……………………… 45 British Airways (K)………………………………… 12 BTG (NL)…………………………………………… 12
C
C-Tech Innovation………………………………… 30 Cardio3 Biosciences (B)… ……………………… 29 Celon Pharma Ltd. (PL)…………………………… 32 Chemtex Italia… ……………………………… 12, 30 Chiesi Farmaceutici S.p.A. (I)… ………………… 30 Chiron Therapeutics Europe (GER)……………… 45 Circassia Ltd. (UK)………………………………… 29 Clariant (GER)… ………………………………… 12 Clasado Ltd. (UK)… ……………………………… 19 Cobra Biologics (UK)……………………………… 19 Cornerstone Therapeutics Inc. (USA)…………… 30 CSL Behring GmbH (GER)… …………………… 20 CTI Clinical Trail and Consulting Service………… 20 Cytos Biotechnology AG (CH)…………………… 18
D
Daiichi Sankyo (JP)… …………………………… Danaher Group (USA)… ………………………… Dezima Pharma (NL)… ………………………… Diagnostics Biomedal S.L. (E)… ………………… Diamyd Medical AB (S)…………………………… Dompe Farmaceutici S.p.A. (I)…………………… Dong Energy (DK)…………………………………
E
32 24 22 31 18 18 12
e-Therapeutics plc (UK)… ……………………… 28 Elan Corp. (IRL)…………………………………28, 50 Epitherapeutics (DK)……………………………… 25 European Biotechnology Network (B)…………… 34 EvalueScience AG (CH)………………………… 35 ExpreS2ion Biotechnologies (DK)… ………… 25, 47
F
Fisons plc (UK)… ………………………………… 45 Flavopharma (PL)… ……………………………… 32 Forbion Capital Partners (NL)… ………………… 22
G
Galapagos NV (B)………………………………… 19 GE Healthcare (UK)… …………………………… 45 Gedeon Richter Ltd. (HUN)……………………… 32 Genentech Inc. (USA)… ………………………… 18 Genexo (PL)… …………………………………… 32 Genmab A/S (DK)………………………………… 50 Genomica S.A.U. (E)……………………………… 31 GIMV (B)…………………………………………… 29 GlaxoSmithKline (UK)… ……………………… 19, 20 GlaxoSmithKline Biologicals (B)… ……………… 20 Grünecker Patent- und Rechtsanwälte (GER)…… 16
H
H. Lundbeck A/S (DK)… ………………………… 15 Hemocue AB (S)… ……………………………… 24 High-Tech Gründerfonds Management (GER)… 15 Hospira One 2 One (USA)… …………………… CP4
I/J
Intercell AG (A)… ………………………………… 27 Iris Pharma (F)… ………………………………… 20 Janssen Pharmaceutica N.V. (B)… ……………… 15
K/L
KBC Group NV (B)………………………………… 32 Kempen & Co (NL)… ………………… CP2, 21, 35 KWS Saat AG (GER)… …………………………… 27 Les Laboratoires Servier S.A. (F)………………… 20 Liconic AG (LI)… ………………………………… 27 Liconic Services Deutschland GmbH… ………… 27 Life Science Austria LISA (A)………………………… 9 Lipid System (PL)… ……………………………… 32 Lipocalyx GmbH (GER) … ……………………… 21 Lipopharm (PL)…………………………………… 32 Lundbeck A/S (DK)… …………………………… 24 Lundbeckfond Ventures (DK)… ………………… 25
M
Mabion S.A. (PL)… ……………………………… 32 Marine Bioproducts AS (N)… …………………… 25 Merck & Co. Inc (USA)… ………………………… 45 Merck KGaA (GER)… …………………15, 19, 31, 45 Merck Millipore Corp.… ………………………… 31 Merck Serono Ventures (CH)… ………………… 25 Mitsubishi Tanabe Pharma (JP)… ……………… 19 Molecular Devices Ltd. (USA)… ………………… 48 Monsanto (USA)… ……………………………… 14 Myriad Genetics (USA)…………………………… 35
N
Nanobiotix S.A. (F)… …………………………… 45 New Science Ventures (USA)… ………………… 22 Noscira S.A. (E)…………………………………… 30 Novamont S.p.A. (I)… …………………………… 30 Novartis AG (CH)… ……………………… 19, 45, 50 Novartis Europharm Ltd. (UK)…………………… 20 Novo Nordisk A/S (DK)…………………………… 24 Novo Seed (DK)… ……………………………… 25
O
OBN Ltd. (UK)… ………………………………… Onclave Therapeutics Ltd. (USA)………………… OncoEthix S.A. (CH)……………………………… Orphan Technologies (CH)… …………………… Orphazyme AS (DK)……………………………… Osborne Clarke (GER)… …………………………
13 20 19 27 20 41
FREE EXCERPT
P
Pfizer Inc. (USA)…………………………… 18, 20, 45 PharmaMar (Grupo Zeltia) (E)………………… 7, 30 Philips Applied Technologies (NL)… …………… 35 Phytopharm (UK)… …………………………… 18, 23 Pierre Fabre Oncology Laboratories (F)… ……… 45 PLIVA d.d. (HR)… ………………………………… 45 Probiodrug AG (GER)… ………………………… 45 Promethera (B)…………………………………… 29 Prometheus Inc. (USA)…………………………… 35 PromoCell GmbH (GER)… ……………………… 48 Prosensa BV (NL)… ……………………………… 45 Prosonix plc (UK)… ……………………………… 45 Proteon Pharmaceuticals Ltd. (PL)… …………… 32 Pure Biologics (PL)… …………………………… 32
Q/R
Qiagen NV (GER)… …………………………… 29, 35 Quest Diagnostics Inc. (USA)… ………………… 24 Quinten (F)… …………………………………… 28 Radiometer Medical (DK)………………………… 24 Ranbaxy Laboratories Ltd. (IND)………………… 45 Reed Exhibitions Japan Ltd (JP)… ……………… CP3 Regeneron Pharmaceuticals Inc. (USA)… ……… 18 Roche AG (CH)… ………………………… 18, 26, 35 Roche Pharma AG (GER)…………………………… 3 Rodon Biologics (PT)… ………………………… 31 Royalty Pharma (USA)… ………………………… 28 Rxmidas Pharmaceuticals Co. Ltd. (VRC)… …… 32
S
SALANS LLP (GER)… ………………………… 39, 42 Sanofi SA (F)… …………………… 15, 20, 24, 35, 45 Santhera Pharmaceuticals (CH)… ……………… 22 Sartorius Stedim Biotech GmbH (GER)… ……… 26 Scienceventure (PL)… …………………………… 32 Seed Capital Denmark (DK)……………………… 25 Selvita sp. z o.o. (PL)……………………………… 32 Skelettal Therapy Support S.A. … ……………… 28 Spirogen Ltd. (UK)………………………………… 29 Statoil (N)… ……………………………………… 25 Stem Cell Spin (PL)… …………………………… 32 Swiss Biotech Association (CH)… ……………… 11
T
t-cell Europe GmbH (GER)… …………………… Taros Chemicals GmbH & Co. KG (GER)………… TCI Laboratories (PL)……………………………… TiGenix BV (B)… ………………………………… TMC Pharma Services Ltd. (UK)… ………………
26 36 32 29 20
U
U3 Pharma GmbH (GER)………………………… 32 UCB Pharma SA (B)… …………………… 15, 18, 29 UPM (FI)…………………………………………… 12 USP Life Science (PL)… ………………………… 32
V
Vaximm Holding AG (CH)………………………… Viken Skog SA (N)………………………………… Viva Biotech (VRC)… …………………………… Vossius und Partner (GER)… ……………………
18 25 50 43
W
Wallinger, Ricker, Schlotter, Tostmann (GER)…… 37 Watson Group… ………………………………… 45 Wyeth (USA)… …………………………………… 45
X/Z
Xellia Pharmaceuticals… ………………………… 25 Zeltia-Group (E)………………………………… 30, 31 Zytoprotec (A)… ………………………………… 27
Parenteral Contract Manufacturing Service of Hospira
Our comfort zone is global parenteral manufacturing • Biologics • Highly Potent Drugs • Cytotoxics
• • • •
Betalactams Controlled Substances Sterile Compounding Single-Use Technology
• Lyophilization • Global Regulatory Services • QP Release
Zagreb, Croatia
Chennai, India
Discover your comfort zone at one2onecmo.com Get your custom report online or contact One 2 One. Call +1-224-212-2267 or +44 (0) 1926 835 554 or e-mail one2one@hospira.com
Your Parenteral Comfort Zone Parenteral Contract Manufacturing Service of Hospira
P11-3517A-Jan., 12